XT 1061
Alternative Names: XT-1061; XTYW-001Latest Information Update: 14 Mar 2024
Price :
$50 *
At a glance
- Originator Xian Xintong Pharmaceutical Research
- Class Antivirals
- Mechanism of Action Nucleocapsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 18 Jul 2023 Phase-I clinical trials in Hepatitis B (In volunteers) in China (PO) (NCT06280534)